On Tuesday, Coya Therapeutics, Inc. (NASDAQ:COYA) released results from the placebo-controlled Phase 2 trial of LD IL-2 in patients with mild to moderate Alzheimer’s Disease. The data was shared at ...
BARCELONA, Spain--(BUSINESS WIRE)--Almirall S.A. (BME: ALM), a global pharmaceutical company focused on medical dermatology, today announced the initiation of the phase I study evaluating the safety, ...
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) ...
Adam Broerman, a graduate student in the University of Washington’s Institute for Protein Design, studies an engineered protein that can turn off protein interactions. (IPD Photo / Ian Haydon) The ...
The immune system is a complex network of cells and proteins with a simple job. Defend the body against infection. To do that, the cells must recognize and destroy infecting viruses or bacteria. In ...
Results are based on a study of low-dose interleukin-2 (IL-2) carried out at Dana-Farber Cancer Institute. New real-world evidence shows low-dose interleukin-2 (LD IL-2) is safe and well tolerated at ...
BIRMINGHAM, Ala. – The immune system has a biological telecommunications system — small proteins known as interleukins that send signals among the leukocyte white blood cells to control their defense ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback